BU
CRL icon

BBVA USA’s Charles River Laboratories CRL Stock Holding History

BBVA USA’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.25M Sell
5,458
-449
-8% -$186K 0.13% 160
2021
Q2 		$2.19M Buy
+5,907
New +$1.97M 0.12% 164

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BBVA USA's CRL Position: Q3 2021 in Review

BBVA USA reduced its Charles River Laboratories (CRL) stake by 7.6% in Q3 2021, selling an estimated $186K and leaving 5,458 shares worth $2.25M. The position accounts for 0.13% of the portfolio, ranked #160.

BBVA USA first reported a position in CRL in Q2 2021 and has held it in 2 quarters since. 676 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

  • BBVA USA held 5,458 shares of Charles River Laboratories worth $2.25M as of Q3 2021.
  • BBVA USA sold 449 Charles River Laboratories shares in Q3 2021, an estimated $186K.
  • Charles River Laboratories made up 0.13% of BBVA USA's portfolio in Q3 2021, its #160 holding.
  • BBVA USA first reported a position in Charles River Laboratories in Q2 2021 and has held it in 2 quarters since.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.